Key Sectors
Medical Technology

Germany is, after the United States, the second most important medical technology developer in the world: approximately 30% of German production originates in Bavaria. The worldwide appreciation of the “made in Germany” trademark directly impacts the Bavarian market and makes it a highly valued manufacturer of products, techniques and cutting-edge apparatus. The medical sector in Canada, on the other hand, obviously stands at the bottom of a forthcoming economic growth curb, with its aging technical and diagnostic equipment and changing demographics.

Bavaria, cutting-edge platform

Bavaria, among few European regions, contains a wide range of businesses, be they SMEs or leading multinational companies such as Siemens Medical Technology, headquartered in Erlangen. With a thorough know-how in fundamental R&D and modern infrastructures, Bavaria is ideally positioned on the high-potential growing market of medical technologies (MT).
Almost 70% of Bavarian sales in MT are made abroad. 20% of the 150,000 German employees in medical products manufacturing are located in Bavaria. The Bavarian health system's quality is world-renowned: its reputation is due to the extent and excellence of its services, and to the great number of infrastructures contributing to patients' well-being. The Bavarian health system comprises:
  • 400 hospitals (complete care), officially certified
  • 48,000 doctors and 10,000 dentists
  • 341 prevention care and rehabilitation infrastructures.
The Erlangen-Nurnberg and Munich regions are two world-class hubs of cutting-edge MT skills. Erlangen-Nurnberg features world famous expertise in radiology, medical physics and pharmaceutical and viral research. Munich, for its part, contains world-famous clinics and institutions (university and other), particularly in non-invasive and computer-assisted processes.
Besides a myriad of highly specialized SMEs, several multinational corporations are located in Bavaria: Siemens Medical Solutions, General Electric (with a European research centre in Garching), Baxter, Fresenius Medical Care, GlaxoSmithKline, Novartis Pharma, Roche, Brainlab, etc.



The sector of medical technologies in Quebec ranks among the “emerging sectors” since R&D has really been developing there only since the 1990s. The public health system in Quebec, a pioneer in the 1980s but now facing several major challenges, generates a business volume of approximately CA$23 billion annually, and experts forecast 3 to 5% growth in coming years, based on demographic projections of an aging population. There is a focus on orthopedics (artificial limbs, spinal column treatments), as well as cardio-vascular and diabetes specialties.
The main client of the MT sector in Quebec is the state, but public health has been undergoing a thorough renovation process for several years. As elsewhere in Canada, diagnostics and hospital equipment are aging and insufficient, which implies extended waiting lists for patients.
Most fundamental R&D activities are concentrated in Montreal. There and in Quebec City, several major projects are underway: medical clinics and public hospitals, for a total investment of 5 billion C$. These massive investment projects offer excellent business opportunities to Bavarian companies.
Among companies present in Quebec are niche SMEs such as Victhom Bionique and CryoCath, but also pharmaceutical giants such as AstraZeneca, Johnson&Johnson, Merck Frosst, Novartis, Pfizer, Roche Diagnostics, Sanofi-Aventis and Wyeth.
For further information: Canada's Medical Technologies Companies' Association (MEDEC), information about the biotechnologies sector in Quebec,